Biotech News

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Regeneron Pharmaceuticals (REGN)investor.regeneron.com2026-05-29 04:03 ESTCompany update

Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biologics-driven biopharmaceutical company built around antibody science, specialty-market execution, and a durable R&D engine. Investors watch both the commercial base and the next wave of pipeline readouts.

Recent company news

REGNRegeneron Pharmaceuticals2026-06-04 15:05:54 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

REGNRegeneron Pharmaceuticals2026-05-22 15:05:36 EST

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

REGNRegeneron Pharmaceuticals2026-05-22 01:02:40 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

REGNRegeneron Pharmaceuticals2026-05-18 15:01:45 EST

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States